CME GroupCME -4.41%81 EBITDA Margin % is 87.11% as of Mar. 2026, which is 10% above its 10-year median of 79.13. GuruFocus rates CME with a GF Score™ of 81/100 and a GF Value™ of $270.89 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 666 Capital Markets companies, CME Group ranks better than 87.99% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. CME Group's EBITDA for the
three
months ended in Mar. 2026 was $1,638 Mil. CME Group's Revenue for the
three
months ended in Mar. 2026 was $1,880 Mil. Therefore, CME Group's EBITDA margin for the quarter that ended in Mar. 2026 was 87.11%.
CME Group (NAS:CME) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CME Group EBITDA Margin % Related Terms
CME Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CME Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Financial Data & Stock Exchanges subindustry, CME Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CME Group EBITDA Margin % vs Capital Markets Industry
For the Capital Markets industry and Financial Services sector, CME Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CME Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CME Group (CME) has a EBITDA Margin % of 87.11% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CME Group and its competitors. This is 10% above median its historical median of 79.13. Over the past decade, CME Group's EBITDA Margin % has ranged from 68.63 to 90.31. According to the industry distribution chart, CME Group ranks #80 out of 666 companies in the Capital Markets industry, placing it in the top 12%.
Is CME Group's EBITDA Margin % too high?
CME Group's current EBITDA Margin % of 87.11% is 10% above median its 10-year median of 79.13. Over the past 10 years, this metric has ranged from a low of 68.63 to a high of 90.31. The Capital Markets industry median EBITDA Margin % is 20.73. CME Group's value of 87.11% is 320.2% above this industry median. Based on the distribution chart, CME Group ranks #80 out of 666 companies in the Capital Markets industry, which is in the top quartile — a strong position relative to peers. Overall, CME Group has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CME Group's EBITDA Margin % compare to ICE and MCO?
According to the Capital Markets industry distribution chart, CME Group ranks #80 out of 666 companies for EBITDA Margin %. This places CME Group in the top 12% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 20.73. CME Group's value of 87.11% is 320.2% above this benchmark. Historically, CME Group's own EBITDA Margin % has ranged from 68.63 to 90.31 over the past decade. While the company's 10-year median is 79.13 vs. the industry median of 20.73, CME Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Capital Markets company?
The median EBITDA Margin % among Capital Markets companies is 20.73, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CME Group's current EBITDA Margin % of 87.11% is 320.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CME Group and its competitors. For the Capital Markets industry, the median EBITDA Margin % is 20.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CME Group's current EBITDA Margin % is 87.11%, which is 10% above median its own 10-year median of 79.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CME Group stock overvalued right now?
Based on GuruFocus' analysis, CME Group (CME) is currently considered Modestly Undervalued. The stock's GF Value™ is $270.89, compared to a current price of $231.58 — trading 14.5% below its estimated fair value. The current EBITDA Margin % is 87.11%, which is 10% above median its 10-year median of 79.13 and 320.2% above the Capital Markets industry median of 20.73. CME Group's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CME Group (CME), the current EBITDA Margin % is 87.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CME Group (CME) Overvalued in 2026?
Based on GuruFocus' analysis, CME Group stock appears to be undervalued.
The current stock price of $231.58 is trading 14.5% below its estimated GF Value™ of $270.89.
GuruFocus considers CME Group to be Modestly Undervalued.
Key valuation signals for CME:
EBITDA Margin %: 87.11% (10% above median its 10-year median of 79.13)
GF Value™: $270.89 vs. price of $231.58 (14.5% below fair value)
Industry Position: 320.2% above the Capital Markets median (#80 of 666)
No single metric tells the full story. See the CME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indexes, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
81GF Score
Get the complete analysis for CME
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CME has been successfully added to your 
